E.H. Tan

1.5k total citations · 1 hit paper
46 papers, 1.1k citations indexed

About

E.H. Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E.H. Tan has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in E.H. Tan's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (7 papers). E.H. Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (7 papers). E.H. Tan collaborates with scholars based in Singapore, China and Germany. E.H. Tan's co-authors include Swan Swan Leong, Wan‐Teck Lim, Chee‐Keong Toh, Balram Chowbay, Ka-wing Fong, Siew Wan Hee, Peter Ang, Nancy Wong, U. Gatzemeier and Kian Fong Foo and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

E.H. Tan

43 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney

2024 53 citations Yanjuan Hou, E.H. Tan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E.H. Tan Singapore	16	605	399	283	211	203	46	1.1k
Édith Borcoman France	17	948 1.6×	419 1.1×	69 0.2×	239 1.1×	150 0.7×	50	1.3k
Enzo Maria Ruggeri Italy	22	681 1.1×	535 1.3×	98 0.3×	274 1.3×	354 1.7×	103	1.4k
Dinesh Chandra Doval India	24	1.2k 1.9×	673 1.7×	68 0.2×	323 1.5×	367 1.8×	101	1.9k
Lukas Weiß Austria	20	544 0.9×	189 0.5×	52 0.2×	246 1.2×	101 0.5×	79	1.1k
Carla van Herpen Netherlands	13	834 1.4×	606 1.5×	979 3.5×	459 2.2×	864 4.3×	29	1.9k
Elona Juozaitytė Lithuania	17	397 0.7×	143 0.4×	40 0.1×	169 0.8×	227 1.1×	86	842
Luciano de Souza Viana Brazil	18	492 0.8×	396 1.0×	225 0.8×	342 1.6×	137 0.7×	37	968
Shinya Ueda Japan	18	599 1.0×	728 1.8×	76 0.3×	302 1.4×	419 2.1×	67	1.3k
Antonio Jirillo Italy	15	595 1.0×	307 0.8×	456 1.6×	137 0.6×	424 2.1×	60	1.1k

Countries citing papers authored by E.H. Tan

Since Specialization

Citations

This map shows the geographic impact of E.H. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.H. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.H. Tan more than expected).

Fields of papers citing papers by E.H. Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.H. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.H. Tan. The network helps show where E.H. Tan may publish in the future.

Co-authorship network of co-authors of E.H. Tan

This figure shows the co-authorship network connecting the top 25 collaborators of E.H. Tan. A scholar is included among the top collaborators of E.H. Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.H. Tan. E.H. Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Niu, Huimin, E.H. Tan, Xing Wan, et al.. (2023). CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function. Renal Failure. 45(2). 2292753–2292753. 15 indexed citations

Tan, E.H., et al.. (2023). Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction. Basic & Clinical Pharmacology & Toxicology. 133(6). 757–769. 8 indexed citations

Qi, Jiaxin, et al.. (2023). Triglyceride-Glucose Index is Significantly Associated with the Risk of Hyperuricemia in Patients with Nonalcoholic Fatty Liver Disease. Diabetes Metabolic Syndrome and Obesity. Volume 16. 1323–1334. 10 indexed citations

Tan, E.H., Wan‐Teck Lim, Mei‐Kim Ang, et al.. (2018). Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Annals of Oncology. 29. ix161–ix161. 5 indexed citations

Park, K., E.H. Tan, L. Zhang, et al.. (2016). 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7). Annals of Oncology. 27. ix140–ix141.

Paz‐Ares, Luis, E.H. Tan, L. Zhang, et al.. (2016). Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7). Annals of Oncology. 27. vi580–vi580. 9 indexed citations

Tan, Wan Ling, et al.. (2016). 139PD: Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs. Journal of Thoracic Oncology. 11(4). S117–S117. 3 indexed citations

Park, K., E.H. Tan, Vera Hirsh, et al.. (2016). 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. Journal of Thoracic Oncology. 11(4). S117–S118. 3 indexed citations

Park, K., E.H. Tan, L. Zhang, et al.. (2015). LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7). Annals of Oncology. 26. ix161–ix161. 12 indexed citations

10.

Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations

11.

Ngeow, Joanne, Wan‐Teck Lim, Swan Swan Leong, et al.. (2010). Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Annals of Oncology. 22(3). 718–722. 53 indexed citations

12.

Tan, E.H., Janusz Rolski, Tomasz Grodzki, et al.. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 20(7). 1249–1256. 56 indexed citations

13.

Lim, Wan‐Teck, E.H. Tan, Chee‐Keong Toh, et al.. (2009). Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors. Annals of Oncology. 21(2). 382–388. 116 indexed citations

14.

Ho, Jcm, E.H. Tan, Swan Swan Leong, et al.. (2003). A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaıve patients with metastatic or locally advanced non-small cell lung cancer. Respiratory Medicine. 97(7). 796–803. 5 indexed citations

15.

Foo, Kian Fong, E.H. Tan, Swan Swan Leong, et al.. (2002). Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Annals of Oncology. 13(1). 150–156. 94 indexed citations

16.

Souquet, P.-J., E.H. Tan, José Rodrigues Pereira, et al.. (2002). GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients. Annals of Oncology. 13(12). 1853–1861. 50 indexed citations

17.

Tan, E.H., K. Khoo, Joseph Wee, et al.. (1999). Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Annals of Oncology. 10(2). 235–238. 118 indexed citations

18.

Tan, E.H., et al.. (1998). Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Annals of Oncology. 9(3). 327–329. 48 indexed citations

19.

Tan, E.H., et al.. (1995). Exercise Systolic Arterial Blood Pressure in Middle-Aged Women with Normal and Elevated Arterial Blood Pressure. International Journal of Sports Medicine. 16(1). 61–65.

20.

Wijnen, H.J., et al.. (1988). Variations in Exercise Systolic Blood Pressure in Physically Active Middle-Aged Men with Normal and Elevated Blood Pressure. International Journal of Sports Medicine. 9(6). 412–416. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact